READ BEFORE ENTERING; This website is for information purposes only; we are not diagnosing, treating, curing, mitigating, or preventing any disease or medical condition by providing the information contained herein. Before beginning any natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.
Serious Side Effects
Serious and life-threatening side effects of ADHD medications include rapid heartbeat and heart rhythm irregularities. Stimulant ADHD medications increase heart rate and blood pressure, and serious adverse cardiovascular events such as heart attacks and sudden death as well as strokes can occur, according to Food and Drug Administration: “Communication about an Ongoing Safety Review of Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder” (December 2011).
Concerns related to adverse effects:
- Cardiovascular events: CNS stimulant treatment has been associated with sudden death in children and adolescents with preexisting structural cardiac abnormalities, and sudden death, stroke, and MI have been reported in adults.
- Psychiatric disorders: Use with caution in patients with preexisting psychosis (may exacerbate symptoms of behavior and thought disorder) or bipolar disorder (may induce mixed/manic episode). New-onset psychosis or mania may occur with stimulant use.
- Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold, leading to new onset or breakthrough seizure activity. Discontinue in the presence of seizures.
- Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including the Raynaud phenomenon
- Priapism: Prolonged (>4 hours), painful, and nonpainful erections, sometimes requiring surgical intervention, have been reported in pediatric and adult patients, according to the manufacturers’ labeling and a 2013 FDA warning.
- Visual disturbance: Difficulty in accommodation and blurred vision have been reported with the use of stimulants.
- Cardiovascular disorders: CNS stimulants may increase heart rate and blood pressure; in pediatric patients
Pediatric: The Use of stimulants has been associated with appetite suppression, weight loss, and slowing of growth rate; monitor growth rate, height, and weight during treatment. Treatment interruption may be necessary for patients who are not increasing in height or gaining weight as expected.
Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse
Daytrana: Transdermal system may cause dermal reactions: Chemical leukoderma and contact sensitization; in a one-year tolerability study, the majority of subjects who withdrew (7%) did so due to dermal reactions. Chemical leukoderma is a persistent loss of skin pigmentation at and around the application site, as well as at distant sites from the application site.
ADHD/ADD Real or Man-Made & the Dangers of the Drugs
There is an abundance of doctors and scientists worldwide that agree that ADHD is a human-made disorder. The pharmaceutical industry has created this disorder to medicate another group of people—your children. And what a vast market it is. Over six million children are on psychotropic drugs, some as young as age two. This is where the insanity comes in. Let’s take a look at an unbrainwashed point of view. Wipeout everything you think you know about ADHD for just a moment and follow along if you will. Pharma has spent billions of dollars to convince the world that this disease exists where it may not.
Not all countries have a 9% rate of ADHD among their children.
France has 0.5% of its child population diagnosed with ADHD. The USA has 9% of its child population, taking amphetamines for this so-called disease. In the USA, we call ADHD occuring in epidemic proportions. No other countries have this epidemic.
The most common stimulants used to treat ADHD are methylphenidate and dextroamphetamine; these are generic drugs marked under several brand names and are tested by the Rxight® genetic test.
- methylphenidate (Concerta, Daytrana, Metadate CD, Metadate ER, Methylin, Methylin ER, Ritalin, Ritalin-LA, Ritalin-SR)
- dexmethylphenidate HCl (Focalin, Focalin XR)
- dextroamphetamine sulfate (Dexedrine, Dexedrine Spansules, Dextroamphetamine ER, Dextrostat)
- lisdexamfetamine dimesylate (Vyvanse)
- amphetamine, mixed salts (Adderall, Adderall XR)
- methamphetamine (Desoxyn)
“ADHD is fraud intended to justify starting children on a life of drug addiction,” said Dr. Edward C. Hamlyn, a founding member of the Royal College of General Practitioners, back in 1998 about the phony condition. Adding to this sentiment, psychiatrists Peter Breggin and Sami Timimi, both of whom oppose pathologizing the symptoms of ADHD, say that ADHD is more of a social construct than it is an objective “disorder.”
“Remember, there are two ways drug companies can make money: Invent new drugs, and invent new diseases already invented drugs can treat,” writes Dr. Jay Parkinson, M.D., M.P.H., about the fake disease-creation industry. “In the past decade or so, Big Pharma has created no less than ten new novel drugs per year,” he adds, noting that many of the people who have been told they suffer from ADHD actually suffer from “the consequence of bad design,” meaning a conventional social and educational system that is unable and unwilling to recognize unique individuality.
Serious Cardiovascular Events
Sudden Death and Pre-Existing Structural Cardiac Abnormalities or Other Serious Heart Problems
Children and Adolescents
Sudden death has been reported in association with CNS stimulant treatment at usual doses in children
and adolescents with structural cardiac abnormalities or other serious heart problems. Although some
serious heart problems alone carry an increased risk of sudden death, stimulant products generally
should not be used in children or adolescents with known serious structural cardiac abnormalities,
cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place
them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at
usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults
have a greater likelihood than children of having serious structural cardiac abnormalities,
cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac
problems. Adults with such abnormalities should also generally not be treated with stimulant drugs.
Hypertension and Other Cardiovascular Conditions
Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and
average heart rate (about 3-6 bpm), and individuals may have larger increases. While the mean
changes alone would not be expected to have short-term consequences, all patients should be
monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients
whose underlying medical conditions might be compromised by increases in blood pressure or heart
rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or
Assessing Cardiovascular Status in Patients being Treated with Stimulant Medications
Children, adolescents, or adults who are being considered for treatment with stimulant medications
should have a careful history (including assessment for a family history of sudden death or ventricular
arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further
cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram).
Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other
Reference ID: 3303787
symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac
Psychiatric Adverse Events
Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder
in patients with a pre-existing psychotic disorder.
Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar
disorder because of concern for possible induction of a mixed/manic episode in such patients. Prior to
initiating treatment with a stimulant, patients with comorbid depressive symptoms should be
adequately screened to determine if they are at risk for bipolar disorder; such screening should include
a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.
Emergence of New Psychotic or Manic Symptoms
Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania
in children and adolescents without a prior history of psychotic illness or mania can be caused by
stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal
role of the stimulant, and discontinuation of treatment may be appropriate.
In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in
about 0.1% (4 patients with events out of 3,482 exposed to methylphenidate or amphetamine for
several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.
Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has
been reported in clinical trials and the postmarketing experience of some medications indicated for the
treatment of ADHD including methylphenidate. Although there is no systematic evidence that
stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be
monitored for the appearance of or worsening of aggressive behavior or hostility.
Long-Term Suppression of Growth
Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either
methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic
subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to
the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per
week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm
less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth
rebound during this period of development. In the double-blind placebo-controlled study of Ritalin
LA® (methylphenidate hydrochloride) extended-release capsules, the mean weight gain was greater for
patients receiving placebo (+1.0 kg) than for patients receiving Ritalin LA (+0.1 kg). Published data
are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of
growth, however, it is anticipated that they likely have this effect as well. Therefore, growth should be
monitored during treatment with stimulants, and patients who are not growing or gaining height or
weight as expected may need to have their treatment interrupted.
Reference ID: 3303787
There is some clinical evidence that stimulants may lower the convulsive threshold in patients with
prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very
rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence
of seizures, the drug should be discontinued.
Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.
Use in Children Under Six Years of Age
Ritalin LA should not be used in children under six years of age, since safety and efficacy in this age
group have not been established.
Ritalin LA should be given cautiously to patients with a history of drug dependence or alcoholism.
Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees
of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful
supervision is required during withdrawal from abusive use, since severe depression may occur.
Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that
may require follow-up.
Periodic CBC, differential, and platelet counts are advised during prolonged therapy.
Information for Patients
Prescribers or other health professionals should inform patients, their families, and their caregivers
about the benefits and risks associated with treatment with methylphenidate and should counsel them
in its appropriate use. A patient Medication Guide is available for Ritalin LA. The prescriber or health
professional should instruct patients, their families, and their caregivers to read the Medication Guide
and should assist them in understanding its contents. Patients should be given the opportunity to
discuss the contents of the Medication Guide and to obtain answers to any questions they may have.
The complete text of the Medication Guide is reprinted at the end of this document.
Patients should be advised to avoid alcohol while taking RITALIN LA. Consumption of alcohol while
taking RITALIN LA may result in a more rapid release of the dose of methylphenidate.
Adverse Events with Other Methylphenidate HCl Dosage Forms
Nervousness and insomnia are the most common adverse reactions reported with other
In children, loss of appetite, abdominal pain, weight loss during prolonged
therapy, insomnia, and tachycardia may occur more frequently; however, any of the other adverse
reactions listed below may also occur.
Other reactions include:
- pulse increased or decreased,
- abdominal pain,
- hypersensitivity reactions including skin rash,
- urticaria, fever,
- erythema multiforme with histopathological findings of necrotizing vasculitis,
- thrombocytopenic purpura
- weight loss during prolonged therapy
- rare reports of Tourette’s syndrome,
- toxic psychosis
- blood pressure increased or decreased; cerebrovascular vasculitis; cerebral occlusions;
cerebral hemorrhages and cerebrovascular accidents
- leukopenia and/or anemia
- abnormal liver function,
- ranging from transaminase elevation to hepatic coma
- transient depressed mood,
- aggressive behavior
scalp hair loss Very rare reports of neuroleptic malignant syndrome (NMS) have been received, and, in most of these,
patients were concurrently receiving therapies associated with NMS. In a single report, a ten-year-old
boy who had been taking methylphenidate for approximately 18 months experienced an NMS-like
event within 45 minutes of ingesting his first dose of venlafaxine. It is uncertain whether this case
represented a drug-drug interaction, a response to either drug alone, or some other cause.
This website is for information purposes only; we are not diagnosing, treating, curing, mitigating, or preventing any disease or medical condition by providing the information contained herein. Before beginning any natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.